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Abstract
Background: Prior to using a generic patient-reported outcome measure (PRO), the measure
should be validated within the target population. The purpose of the current study was to validate
two generic measures in patients with type 2 diabetes.
Methods: Patients with type 2 diabetes in Scotland and England completed two generic measures:
EQ-5D and Psychological General Well-Being Index (PGWB). Two diabetes-specific measures
were administered: ADS and DSC-R. Analyses assessed reliability and validity.
Results: There were 130 participants (53 Scotland; 77 England; 64% male; mean age = 55.7 years).
Responses on the EQ-5D and PGWB reflected moderate impairment consistent with previous
diabetes samples: mean EQ-5D Index score, 0.75; EQ-5D VAS, 68.8; PGWB global score, 67.9. All
scales of the PGWB demonstrated good internal consistency reliability (Cronbach's alpha = 0.77
to 0.97). The EQ-5D and PGWB demonstrated convergent validity through significant correlations
with the ADS (r = 0.48 to 0.61), DSC-R scales (r = 0.33 to 0.81 except ophthalmology subscale),
and Body Mass Index (r = 0.15 to 0.38). The EQ-5D and PGWB discriminated between groups of
patients known to differ in diabetes-related characteristics (e.g., history of hypoglycemia).
Conclusion: Results support the use of the EQ-5D and PGWB among patients with type 2
diabetes, possibly in combination with condition-specific measures.
Background
Patient-reported outcome measures (PROs) that assess
health-related quality of life (HRQL) and related con-
structs are often categorized as either generic or condition-
specific [1-3]. Generic measures are designed for use
among diverse populations with a broad range of medical
conditions. These instruments can also be used to charac-
terize healthy samples without a particular medical condi-
tion. In contrast, condition-specific measures are relevant
to a particular group of patients, and they have been
developed to assess specific populations, quantify aspects
of functioning, and examine the impact of particular med-
ical conditions or treatments.
A substantial body of literature has focused on comparing
generic and condition-specific measures, while identify-
ing advantages of each. Compared with generic measures,
the primary advantage of condition-specific measures is
that they are usually found to be more responsive to treat-
ment-related change [4-6]. Because of their greater
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responsiveness to change, condition-specific instruments
may be more likely to detect differences between treat-
ment groups in clinical trials [7]. An advantage of generic
PROs is that they can be used to compare among various
populations, make comparisons to the general popula-
tion, and estimate the relative impact of various medical
conditions or treatments [1,2,8,9]. Generic measures also
tend to correlate well with condition-specific measures
[10,11], and in some studies, they have demonstrated
responsiveness or convergent validity that was compara-
ble to condition-specific measures [12-16]. Most impor-
tantly, generic measures are distinct from condition-
specific measures in that they usually assess impact of dis-
ease and treatment on overall functioning or a broader
range of health domains [8,17].
Because generic and condition-specific measures have dif-
ferent strengths and are conceptually distinct, it is often
recommended to administer both types of instruments as
part of a complete outcomes assessment in clinical trials
[5,17-19]. Prior to using a generic measure, however, it is
important that the instrument is shown to be reliable and
valid in the specific population under investigation [9].
Instruments validated in one population will not neces-
sarily perform well among patients with a different medi-
cal condition. Therefore, it is often necessary to validate
generic PROs in multiple populations. The purpose of the
current study was to examine the performance of two
commonly used generic PROs in a sample of patients with
type 2 diabetes, an increasingly prevalent disease associ-
ated with serious health risks and HRQL impairment [20-
27].
One of the two measures evaluated in this study is the
EuroQol EQ-5D, a brief health status instrument fre-
quently used for clinical and economic appraisal [28,29].
The EQ-5D has been used in several large studies involv-
ing patients with type 2 diabetes to provide an estimate of
HRQL and derive utilities, which used to compute qual-
ity-adjusted life years (QALYs) in models evaluating treat-
ment cost-effectiveness [30-35]. However, no studies were
located focusing on validation of the EQ-5D among
patients with type 2 diabetes. The other generic PRO
examined in this study is the Psychological General Well-
Being Index (PGWB), which was developed to measure
self-perception of affective states and to assess a sense of
subjective well-being or distress [36]. The PGWB has been
used in several studies that included patients with type 2
diabetes [37,38], including one study that found adequate
internal consistency reliability and convergent validity
among a sample of 88 Native American patients with type
2 diabetes [39]. However, no studies were located validat-
ing the PGWB in a more general sample of patients with
type 2 diabetes. The current analysis builds on these find-
ings by evaluating these properties among a larger sample
in the United Kingdom, while also assessing known-
groups validity.
Methods
Participants
Participants were required to be (1) diagnosed with type 2
diabetes by a recognized medical professional (as indi-
cated by patient self-report); (2) between 30 and 75 years
old; (3) able to identify the age at which they were first
diagnosed with diabetes; (4) able to read and understand
English; and (5) willing and able to give informed consent
prior to study entry. Patients were not eligible if they had
cognitive impairment, hearing difficulty, or severe psy-
chopathology that could interfere with the ability to com-
plete the study measures. Participants were recruited
through ten advertisements placed in four newspapers in
Scotland and England from June to August of 2005. Inter-
ested patients responded by telephone, and 200 potential
participants were screened to assess whether they met the
study inclusion/exclusion criteria. Of the 200 screened
patients, 132 were available, eligible, and willing to par-
ticipate. Two participants who attended the interview
were unable to complete the questionnaires relevant to
the current analysis. Thus, the current study includes a
sample of 130 individuals with type 2 diabetes.
Measures
EuroQol EQ-5D
This questionnaire assesses functioning in five dimen-
sions: mobility, self-care, usual activities, pain/discom-
fort, and anxiety/depression. Each dimension is assessed
by one item with three response options: no problems,
some problems, and severe problems. Higher scores on
these items indicate greater impairment. Responses to
these five items are used to derive the weighted EQ-5D
index score, which represents overall health with a possi-
ble range from -0.594 to 1.0 [40,41]. After completing the
five dimension items, patients completed the single item
EQ-5D visual analogue scale (VAS), on which they rated
their current health on a scale ranging from 0 (worst imag-
inable health state) to 100 (best imaginable health state).
Higher scores on the index score and VAS indicate better
health status.
Psychological General Well-Being Index (PGWB)
The PGWB is comprised of 22 items in the following 6
dimensions: anxiety (5 items); depressed mood (3 items);
positive well-being (4 items); self-control (3 items); gen-
eral health (3 items); and vitality (4 items). Responses are
rated on a six-point Likert scale ranging from 0 (reflecting
the most distress) to 5 (reflecting the highest level of well-
being) [42]. Scoring approaches for the PGWB have varied
in previously published studies, with the global score
often ranging from 0 to 100 (when items range from 0 to
5) or 22 to 132 (when items range from 1 to 6). For theHealth and Quality of Life Outcomes 2007, 5:47 http://www.hqlo.com/content/5/1/47
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current study, this instrument was scored following the
approach proposed by Chassany et al. [42] in the recently
published user's manual. The six PGWB raw subscale
scores were computed by summing the item responses,
and the raw global score is the sum of the six subscale
scores. Then, these raw scores were transformed to a 0–
100 scale by dividing each raw score by the maximum
possible score, multiplying by 100, and rounding to one
decimal place. Higher scores reflect better well-being.
Appraisal of Diabetes Scale (ADS)
The ADS is a brief 7-item patient-reported scale that
assesses the impact of diabetes on a patient's life. This con-
dition-specific instrument was used to assess criterion
validity of the EQ-5D and PGWB. The items, which were
developed based on theory and previous research, include
"How upsetting is having diabetes for you?" and "To what
degree does your diabetes get in the way of your develop-
ing life goals?". The instrument has been shown to have
acceptable internal consistency reliability, test-retest relia-
bility, and construct validity [43]. Higher scores indicate
greater negative impact of diabetes.
Diabetes Symptom Checklist – Revised (DSC-R)
The DSC-R is a revised version of the DSC-2, which was
developed to measure both the frequency and perceived
discomfort of physical and psychological symptoms asso-
ciated with type 2 diabetes and its potential complications
[44]. Like the ADS, the DSC-R was used to assess validity
of the two generic instruments that were the focus of the
current analysis. For each of the 34 DSC-R items, respond-
ents first indicate whether they have experienced each
symptom in the past month by circling "yes" or "no." If
the patient answers "no," then the item is scored as a 0. If
"yes" is selected, the participant proceeds to rate the per-
ceived discomfort of the symptom on a 5-point scale rang-
ing from 1 (not at all) to 5 (extremely). The instrument
yields a total score and scores on the following subscales:
psychology-fatigue, psychology-cognitive, neurology-
pain, neurology-sensory, cardiology, ophthalmology,
hypoglycemia, and hyperglycemia. The total score and all
subscale scores range from 0 to 5, with higher scores indi-
cating greater symptom burden.
Demographic and clinical information form
Patients completed a brief questionnaire that included
questions on age, sex, ethnicity, living situation, employ-
ment, education, diabetes-related health, and general
health. Participants' weight and height were measured at
the beginning of each interview and recorded on the
demographic and clinical information form so that
patients' Body Mass Index (BMI) could be computed [45].
Items assessing diabetes-related health included questions
asking whether participants had ever experienced hyperg-
lycemia, daytime hypoglycemia, or nighttime hypoglyc-
emia.
Data collection and statistical analysis procedures
Data were collected in Edinburgh and London during
August 2005. All procedures and instruments were
approved by an independent Institutional Review Board,
and all participants provided written informed consent
prior to completing any study measures. After signing the
consent form, participants independently completed the
questionnaires analyzed in the current study.
Statistical analyses were completed using SAS version 8.12
(SAS Institute, Cary, NC). Descriptive statistics were used
to summarize demographic/clinical characteristics and
scores on health status measures. Categorical variables are
summarized in terms of frequencies and percentages, and
for each continuous variable, the mean, standard devia-
tion, median, range, percent at floor, and percent and ceil-
ing are presented. In the current study, there were no
missing data on any of the measures, and therefore, pro-
cedures for handling missing data were not followed.
Internal consistency reliability is the extent to which indi-
vidual items within a scale are related to one another.
Internal consistency was examined for the PGWB sub-
scales and global score using Cronbach's formula for coef-
ficient alpha. Cronbach's alphas greater than 0.70 are
generally considered acceptable [9].
Construct validity refers to the extent to which the instru-
ment measures what it is intended to measure. To assess
the construct validity of the EQ-5D and PGWB, both con-
vergent and known-groups validity were examined. Con-
vergent validity is the degree to which scores from the
instrument undergoing evaluation are related to scores
from an instrument measuring a similar construct. To
examine convergent validity, Spearman correlations were
performed to examine the relationship of the two generic
measures with diabetes-specific patient-reported meas-
ures and patients' BMI. BMI was used as a criterion
because body weight is an important health indicator for
patients with type 2 diabetes. Roughly 40% to 50% of
patients with diabetes meet criteria for obesity [26,46],
and obesity is likely to exacerbate symptoms and meta-
bolic abnormalities of type 2 diabetes, increase the risk of
complications, and complicate the goal of achieving glyc-
emic control [47-50]. Correlation coefficients were inter-
preted based on guidelines proposed by Cohen [51]
suggesting that a correlation of 0.10 is small, 0.30 is mod-
erate, and 0.50 is large. It was hypothesized that the
generic measures under investigation would be signifi-
cantly correlated with the condition-specific measures
and patients' BMI, with correlation coefficients in the
moderate to large range.Health and Quality of Life Outcomes 2007, 5:47 http://www.hqlo.com/content/5/1/47
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Known-groups validity is a scale's ability to discriminate
among groups of patients who are known to differ by a
key indicator. Using t-tests, EQ-5D and PGWB scores were
compared among groups of patients who differed in the
following characteristics: symptom burden as reported on
condition-specific measures; type of pharmacological
treatment (injectable insulin vs. oral medication only);
preference for weight change (patients who would like to
lose weight vs. patients who would like to stay the same
weight); and experience with daytime hypoglycemia,
nighttime hypoglycemia, and hyperglycemia (patients
who had each of these experiences vs. patients who did
not). It was hypothesized that the EQ-5D and PGWB
would discriminate between groups of patients in each of
these comparisons.
Results
Sample description
A total of 130 eligible participants completed the study,
53 in Edinburgh and 77 in London (Table 1). The sample
in London was more ethnically diverse than the sample in
Edinburgh, which was 100% White. There were no other
statistically significant differences between the two geo-
graphic groups with respect to demographics (e.g., gender,
age, marital status, employment) or clinical characteristics
(e.g., BMI, age when first diagnosed with diabetes, current
treatment). Therefore, data from the two cities were
pooled for all analyses.
The majority of participants were male (n = 84; 64.6%),
and the mean age of the total sample was 55.7 years old.
Most of the patients were currently married (n = 79;
60.8%), over a third worked full-time (n = 46; 35.4%),
and over a third were retired (n = 47; 36.2%). The mean
Body Mass Index (BMI) of the total sample was 31.5,
Table 1: Demographic and clinical characteristics
Characteristic Total Sample
 (N = 130)
Edinburgh (N = 53) London (N = 77) p value1
Age (mean, SD) 55.7 (10.3) 56.2 (8.8) 55.4 (11.3) 0.69
Gender (n, %)
Male 84 (64.6%) 33 (62.3%) 51 (66.2%) 0.71
Female 46 (35.4%) 20 (37.7%) 26 (33.8%)
Ethnicity (n, %)
White 105 (80.8%) 53 (100.0%) 52 (67.5%) <0.0001
Black 8 (6.2%) 0 (0.0%) 8 (10.4%)
Indian 8 (6.2%) 0 (0.0%) 8 (10.4%)
Other 9 (6.9%) 0 (0.0%) 9 (11.7%)
Marital Status (n, %)
Married 79 (60.8%) 37 (69.8%) 42 (54.5%) 0.10
Not married 51 (39.2%) 16 (30.2%) 35 (45.5%)
Employment Status (n, %)
Full-time work 46 (35.4%) 19 (35.8%) 27 (35.1%) 0.91
Retired 47 (36.2%) 20 (37.7%) 27 (35.1%)
Other 37 (28.5%) 14 (26.4%) 23 (29.9%)
Education Level (n, %)
Did not complete college degree 86 (66.2%) 40 (75.5%) 46 (59.7%) 0.089
Completed college degree or higher 44 (33.8%) 13 (24.5%) 31 (40.3%)
Body Mass Index2 31.5 (5.4) 32.3 (5.6) 31.0 (5.3) 0.19
Age when Diagnosed with Diabetes (mean, SD) 49.1 (11.2) 49.1 (11.2) 49.2 (11.3) 0.96
Current Treatment (n, %)
Diet and/or exercise alone 14 (10.8%) 6 (11.3%) 8 (10.4%) 0.34
Oral meds alone (no injectable) 85 (65.4%) 31 (58.5%) 54 (70.1%)
Injectable medication with or without other treatment 31 (23.8%) 16 (30.2%) 15 (19.5%)
Other Health Conditions (n, %)
Hypertension (n, %) 48 (36.9%) 17 (32.1%) 31 (40.3%) 0.36
Diabetic retinopathy (n, %) 7 (5.4%) 3 (5.7%) 4 (5.2%) 1.00
Depression or other mental health condition (n, %) 17 (13.1%) 7 (13.2%) 10 (13.0%) 1.00
Other Health Condition(s) (n, %) 56 (43.1%) 25 (47.2%) 31 (40.3%) 0.47
None (n, %) 45 (34.6%) 16 (30.2%) 29 (37.7%) 0.45
1 P value is for comparisons between the Edinburgh sample and the London sample. Continuous variables compared with t-tests; 2-level categorical 
variables such as gender compared with Fisher's exact test; categorical variables with more than two levels were compared with chi-squares.
2 Body Mass Index = (weight in pounds/[height in inches]2) × 703Health and Quality of Life Outcomes 2007, 5:47 http://www.hqlo.com/content/5/1/47
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which is considered to be in the obese range [45]. The
mean age when first diagnosed with diabetes was 49.1
years old. Most participants received oral, but not injecta-
ble medications for treatment of their diabetes (n = 85;
65.4%). A total of 31 participants (23.8%) were treated
with injectable medications, either alone or in combina-
tion with oral medications.
Descriptive statistics and internal consistency reliability
There were no missing data on the EQ-5D (Table 2). The
great majority of the 130 participants reported no prob-
lems on the EQ-5D self-care item (n = 120; 92.3%), while
the other four dimension items reflected greater rates of
difficulty. Roughly one third of participants reported hav-
ing at least some problems in the dimensions of mobility
(n = 42; 32.3%) and usual activities (n = 41; 31.5%).
Approximately a third of patients reported having either
some problems (n = 35; 26.9%) or extreme problems (n
= 8; 6.2%) in the anxiety/depression dimension. The
greatest rates of difficulty were found in the pain/discom-
fort dimension, with half of the sample reporting either
some problems (n = 52; 40.0%) or extreme problems (n
= 13; 10.0%). The pattern of responses was similar in the
London and Edinburgh samples, although the partici-
pants in Edinburgh reported slightly greater rates of prob-
lems in mobility, self-care, and usual activities. The mean
EQ-5D index score of 0.75 and VAS score of 68.8 both
indicate a moderate level of overall impairment in this
sample (Table 3). The mean index score was somewhat
lower for the Edinburgh sample (0.70) than for the Lon-
don sample (0.79). Analysis of floor and ceiling effects
revealed that 40% of the sample had the maximum EQ-
5D index score of 1. The VAS did not have a similar ceiling
effect.
On the PGWB, there were no missing data, and mean sub-
scale scores were similar in the two samples (Table 4). The
greatest impairment was reflected in the vitality subscale,
which had a mean score of 59.5 in the total sample of 130
participants. The positive well-being and general health
Table 3: Distributional Characteristics of EQ-5D Continuous Scales
EQ-5D Scales Mean SD Range % at Floor % at Ceiling
Edinburgh Sample (n = 53)
Index Score 0.70 0.36 -0.24–1.0 0% 41.5%
VAS 68.4 19.1 10.0–98.0 0% 0%
London Sample (n = 77)
Index Score 0.79 0.25 -0.18–1.0 0% 39.0%
VAS 69.1 17.9 11.0–95.0 0% 0%
Total Sample (n = 130)
Index Score 0.75 0.30 -0.24–1.0 0% 40.0%
VAS 68.8 18.3 10.0–98.0 0% 0%
VAS = Visual Analog Scale
Table 2: Frequencies and percentages of participants' responses to the five categorical items of the EQ-5D
Responses EQ-5D Items
Mobility Self-Care Usual Activities Pain/Discomfort Anxiety/
Depression
Edinburgh Sample 
(n = 53)
No problems 34 (64.2%) 47 (88.7%) 33 (62.3%) 26 (49.1%) 38 (71.7%)
Some problems 19 (35.9%) 6 (11.3%) 19 (35.9%) 19 (35.9%) 9 (17.0%)
Extreme problems 0 (0.0%) 0 (0.0%) 1 (1.9%) 8 (15.1%) 6 (11.3%)
London Sample (n 
= 77)
No problems 54 (70.1%) 73 (94.8%) 56 (72.7%) 39 (50.7%) 49 (63.6%)
Some problems 23 (29.9%) 4 (5.2%) 21 (27.3%) 33 (42.9%) 26 (33.8%)
Extreme problems 0 (0.0%) 0 (0.0%) 0 (0.0%) 5 (6.5%) 2 (2.6%)
Total Sample (n = 
130)
No problems 88 (67.7%) 120 (92.3%) 89 (68.5%) 65 (50.0%) 87 (66.9%)
Some problems 42 (32.3%) 10 (7.7%) 40 (30.8%) 52 (40.0%) 35 (26.9%)
Extreme problems 0 (0.0%) 0 (0.0%) 1 (0.8%) 13 (10.0%) 8 (6.2%)Health and Quality of Life Outcomes 2007, 5:47 http://www.hqlo.com/content/5/1/47
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subscales also reflected some impairment (mean scores of
61.1 and 63.4, respectively). Higher scores were found on
the anxiety, depressed mood, and self-control subscales
(69.9, 78.9, and 78.0, respectively). On the depressed
mood subscale, 23.8% of the sample had the maximum
score of 100, indicating that almost a quarter of this sam-
ple reported no problems with depression. The PGWB
demonstrated good internal consistency reliability, with
Cronbach's alphas for the six subscales ranging from 0.77
to 0.92 (Table 5). The alpha for the global score was 0.97.
Convergent validity
Convergent validity of the EQ-5D index score and VAS
were demonstrated through significant correlations with
the ADS, DSC-R, and patients' BMI (Table 6). These corre-
lations were generally in the moderate to large range.
Spearman correlations of the index score and VAS with
the ADS had coefficients of -0.52 and -0.49, respectively
(both p < 0.001). Correlations with the DSC-R total score
were -0.64 and -0.53 (both p < 0.001). Correlations
between the EQ-5D and the DSC-R subscales ranged from
-0.33 to -0.61 (all p < 0.001), except for the correlations
with the ophthalmology subscale which were somewhat
smaller (r = -0.22 and -0.19; both p < 0.05). Correlations
of the EQ-5D index score and VAS with patients' BMI were
-0.27 (p < 0.01) and -0.38 (p < 0.001).
Convergent validity of the PGWB global score was also
supported (Table 6), with the majority of correlations in
the moderate to large range. Correlations of the PGWB
global score with the ADS and the DSC-R total score had
coefficients of -0.61 and -0.71, respectively (both p <
0.001). Correlations of the PGWB global score with the
DSC-R subscales, except the ophthalmology subscale,
ranged from -0.45 to -0.76 (all p < 0.001). The correlation
with patients' BMI was somewhat smaller, but still statis-
tically significant (r = -0.24; p < 0.01).
The PGWB subscales also demonstrated good convergent
validity. Correlations of these six subscales with the ADS
ranged from -0.48 to -0.61 (all p < 0.001). Similarly, all
PGWB subscales had correlations with the DSC-R total
score that were in the large range (r = -0.57 to -0.68; all p
Table 5: Internal consistency reliability of the PGWB
PGWB Number of items 
(k)
Cronbach's alpha 
(std)
Anxiety 5 0.92
Depressed Mood 3 0.88
Positive Well-Being 4 0.90
Self-Control 3 0.80
General Health 3 0.77
Vitality 4 0.90
PGWB Global Score 22 0.97
PGWB = Psychological General Well-Being Index
Table 4: Distributional Characteristics of the PGWB Scales
PGWB Scales Mean SD Range % at Floor % at Ceiling
Edinburgh Sample (n = 53)
Anxiety 70.5 23.9 0.0–100.0 1.9% 9.4%
Depressed Mood 78.0 23.9 13.3–100.0 0% 22.6%
Positive Well-Being 59.9 22.5 0.0–95.0 1.9% 0%
Self-Control 76.5 23.0 0.0–100.0 1.9% 17.0%
General Health 62.3 22.6 0.0–100.0 1.9% 1.9%
Vitality 57.3 22.1 0.0–100.0 1.9% 1.9%
Global Score 66.9 20.9 3.6–94.5 0% 0%
London Sample (n = 77)
Anxiety 69.5 20.7 12.0–100.0 0% 3.9%
Depressed Mood 79.6 20.9 26.7–100.0 0% 24.7%
Positive Well-Being 61.9 21.9 5.0–100.0 0% 1.3%
Self-Control 79.0 18.8 26.7–100.0 0% 15.6%
General Health 64.2 19.3 20.0–100.0 0% 2.6%
Vitality 61.1 21.3 0.0–100.0 1.3% 1.3%
Global Score 68.5 18.1 16.4–94.5 0% 0%
Total Sample (n = 130)
Anxiety 69.9 22.0 0.0–100.0 0.8% 6.2%
Depressed Mood 78.9 22.1 13.3–100.0 0% 23.8%
Positive Well-Being 61.1 22.1 0.0–100.0 0.8% 0.8%
Self-Control 78.0 20.6 0.0–100.0 0.8% 16.2%
General Health 63.4 20.6 0.0–100.0 0.8% 2.3%
Vitality 59.5 21.6 0.0–100.0 1.5% 1.5%
Global Score 67.9 19.2 3.6–94.5 0% 0%
PGWB = Psychological General Well-Being IndexHealth and Quality of Life Outcomes 2007, 5:47 http://www.hqlo.com/content/5/1/47
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< 0.001). Correlations between PGWB subscales and
DSC-R subscales were all in the moderate to large range
and statistically significant (p < 0.001), except for those
involving the DSC-R ophthalmology subscale which were
notably smaller. Correlations with BMI were statistically
significant for four PGWB subscales: positive well-being (r
= -0.19), self-control (r = -0.20), general health (r = 0.28),
and vitality (r = 0.28). The anxiety and depressed mood
subscales of the PGWB were not significantly correlated
with BMI.
Known-groups validity
Known-groups validity of the EQ-5D index score and VAS
was supported in several group comparisons (Table 7).
Both EQ-5D scores significantly discriminated between
groups of patients categorized based on median splits of
their ADS score and DSC-R total score (all p < 0.001).
Groups with higher scores (indicating greater symptom
burden) on these two diabetes-specific instruments had
lower EQ-5D scores (indicating lower HRQL). In addi-
tion, patients who wanted to lose weight (n = 113) had
significantly lower EQ-5D scores than patients who
wanted to stay the same weight (n = 16) (both p < 0.001).
Patients who had experienced daytime hypoglycemia had
significantly lower mean EQ-5D index (p < 0.05) and VAS
(p < 0.001) scores than patients who had not experienced
daytime hypoglycemia. Results followed a similar pattern
for hyperglycemia and nighttime hypoglycemia, although
comparisons were not consistently statistically significant.
The PGWB also discriminated between groups of patients
who differed in scores on diabetes-specific instruments
and clinical characteristics (Table 7). Groups with higher
scores (indicating greater symptom burden) on the ADS
and DSC-R total score had lower PGWB global scores
(indicating lower overall well-being) (both p < 0.001).
Patients who wanted to lose weight (n = 113) had a signif-
icantly lower mean PGWB global score than patients who
wanted to stay the same weight (n = 16) (p < 0.05). The
PGWB global score also discriminated between groups of
patients differing with regard to whether they had experi-
enced daytime hypoglycemia, nighttime hypoglycemia,
and hyperglycemia (all p < 0.05). Known-groups validity
of the PGWB subscales was also supported (Table 8). Sta-
tistically significant group differences were found in most
comparisons involving the anxiety, positive well-being,
self-control, general health, and vitality subscales. The
depressed mood subscale discriminated between groups
of patients determined by median splits on the ADS and
DSC-R, but significant differences on this subscale were
not found in the other group comparisons.
No scales of the EQ-5D or PGWB significantly discrimi-
nated between patients treated with injectable medication
(i.e., insulin with or without concomitant oral medica-
tion; n = 31) and patients treated only with oral medica-
tions. In general, scores were somewhat higher in the oral
treatment group, but these differences between groups
were not statistically significant.
Discussion
Current findings provide support for the use of the EQ-5D
and PGWB in patients with type 2 diabetes. The PGWB
had good internal consistency reliability, and both instru-
ments demonstrated excellent convergent and known-
groups validity. Convergent validity was supported
through consistently significant correlations with self-
report, diabetes-specific symptom impact measures as
well as patients' BMI, an objective health indicator that is
particularly relevant to type 2 diabetes [20,26,52]. Fur-
thermore, both the EQ-5D and PGWB discriminated
between groups of patients who differed in self-reported
impact of diabetes symptoms, preference for weight
change, and experience with hyperglycemia and hypogly-
cemia.
Table 6: Convergent Validity of the EQ-5D and PGWB: Spearman correlations with condition-specific measures and BMI
DSC-R Scales
ADS Total Score Fatigue Cognitive Pain Sensory Cardiology Ophthalmology Hypoglycemia Hyperglycemia BMI1
EQ-5D
Index Score -.52*** -.64*** -.61*** -.46*** -.51*** -.53*** -.56*** -.22* -.44*** -.46*** -.27**
VAS -.49*** -.53*** -.50*** -.43*** -.39*** -.41*** -.45*** -.19* -.33*** -.37*** -.38***
PGWB
Global Score -.61*** -.71*** -.76*** -.61*** -.46*** -.48*** -.54*** -.24** -.56*** -.45*** -.24**
Anxiety -.48*** -.58*** -.62*** -.50*** -.38*** -.37*** -.43*** -.19* -.52*** -.37*** -.15
Depressed Mood -.55*** -.57*** -.65*** -.52*** -.37*** -.33*** -.48*** -.15 -.48*** -.34*** -.16
Positive Well-Being -.61*** -.60*** -.65*** -.56*** -.39*** -.40*** -.45*** -.19* -.52*** -.34*** -.19*
Self-Control -.54*** -.61*** -.61*** -.60*** -.40*** -.42*** -.47*** -.25** -.49*** -.38*** -.20*
General Health -.52*** -.68*** -.66*** -.47*** -.50*** -.58*** -.50*** -.32*** -.44*** -.45*** -.28**
Vitality -.58*** -.67*** -.81*** -.59*** -.38*** -.45*** -.49*** -.19* -.50*** -.43*** -.28***
BMI = Body Mass Index; ADS = Appraisal of Diabetes Scale; DSC-R = Diabetes Symptom Checklist – Revised; PGWB = Psychological General Well-
Being Index; VAS = Visual Analog Scale; 1Body Mass Index = (weight in pounds/[height in inches]2) × 703; *p < 0.05; **p < 0.01; ***p < 0.001Health and Quality of Life Outcomes 2007, 5:47 http://www.hqlo.com/content/5/1/47
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The mean EQ-5D index score of 0.75 is consistent with
EQ-5D ratings in other studies of patients with type 2 dia-
betes. For example, the mean index score was 0.74 in a
sample of 1348 patients in the Netherlands [34] and 0.76
in a sample of 4189 patients from five European countries
[32]. In previous studies, the PGWB has been scored in
several ways (as described in the methods section of the
current manuscript), thus making it difficult to compare
among studies. In the current study, this instrument was
scored using a relatively new standardized approach pro-
posed in the recently published PGWB user's manual.
Using this approach, all subscale scores and the global
score are normalized so that scores have a possible range
of 0 to 100 [42]. The current results provide a benchmark
for these normalized scores among a general sample of
patients with type 2 diabetes in the UK.
Although the two generic measures were found to be valid
in this sample, it would not be ideal to use either instru-
ment as the only PRO in a clinical trial. A published anal-
ysis comparing generic to condition-specific measures
across 43 randomized clinical trials found that the condi-
tion-specific measures were more responsive to change,
particularly in studies with a nonzero therapeutic effect
[6]. Thus, interpretation of trial outcomes based solely on
generic instruments such as the PGWB or EQ-5D could
fail to detect true treatment-related improvement, even
though these two measures do appear to correlate well
with condition-specific instruments. Furthermore, generic
instruments may not capture the specific impairments
within a particular population. For example, although all
participants in the current sample had type 2 diabetes,
40% of the participants had the maximum EQ-5D index
score of 1 which theoretically represents perfect health sta-
tus. This ceiling effect suggests that the brief EQ-5D may
not reflect the health-related problems of all patients with
type 2 diabetes, particularly patients whose symptoms
have an impact on functional domains other than the five
EQ-5D dimensions. Given the different strengths of
generic and condition-specific measures, we recommend
using the EQ-5D and PGWB as part of an overall health
outcomes battery that also includes condition-specific
measures of symptom burden or HRQL. There are several
well-validated instruments designed specifically to assess
outcomes of treatment for type 2 diabetes [53,54], and the
decision regarding which measures to use will depend on
Table 7: Known-groups validity of the EQ-5D and PGWB Global Score: Comparisons between groups of patients
Variable Used to 
Differentiate Groups
Groups EQ-5D Index Score EQ-5D VAS PGWB Global Score
Mean t Value Mean t Value Mean t Value
ADS Median Split ADS Score ≤ 16
(n = 58)
0.88 5.1*** 76.7 5.0*** 78.9 7.3***
ADS Score > 16
(n = 72)
0.65 62.5 59.0
DSC-R Median Split DSC-R Total Score ≤ 0.7
(n = 61)
0.91 6.6*** 78.8 7.0*** 79.6 8.2***
DSC-R Total Score > 0.7
(n = 69)
0.61 60.0 57.5
Preference for Weight 
Change
Lose weight
(n = 113)
0.73 -4.4*** 66.7 -5.0*** 66.5 -2.0*
Stay same
(n = 16)
0.92 83.0 76.9
Experienced 
Hypoglycemia During the 
Day
Yes 
(n = 53)
0.68 -2.6* 62.6 -3.4*** 64.0 -2.3*
No 
(n = 74)
0.82 73.9 71.8
Experienced 
Hypoglycemia During the 
Night
Yes 
(n = 23)
0.60 -3.2** 64.2 -1.5 58.8 -3.0**
No
(n = 101)
0.80 70.6 71.0
Experienced 
Hyperglycemia
Yes
(n = 64)
0.73 -1.1 64.5 -2.8** 64.9 -2.1*
No
(n = 63)
0.78 73.4 71.6
Type of Treatment Injectable
(n = 31)
0.65 -1.8 61.4 -2.0 62.6 -1.3
Oral only
(n = 85)
0.78 70.2 68.9
ADS = Appraisal of Diabetes Scale; DSC-R = Diabetes Symptom Checklist – Revised; PGWB = Psychological General Well-Being Index; VAS = Visual 
Analog Scale; *p < 0.05; **p < 0.01; ***p < 0.001H
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Table 8: Known-Groups Validity of the PGWB Subscales: Comparisons between Groups of Patients
Variable Used
 to Differentiate 
Groups
Groups Anxiety Depressed 
Mood
Positive
Well Being
Self Control General Health Vitality
Mean t Value Mean t Value Mean t Value Mean t Value Mean t Value Mean t Value
ADS Median Split ADS Score ≤ 16
(n = 58)
79.9 5.4*** 89.7 5.9*** 74.3 7.6*** 88.4 6.1*** 73.1 5.5*** 71.2 6.5***
ADS Score > 16
(n = 72)
61.8 70.3 50.4 69.6 55.7 50.1
DSC-R Median 
Split
DSC-R Total Score ≤ 0.7
(n = 61)
81.0 6.3*** 89.5 5.9*** 72.5 6.3*** 89.0 6.8*** 76.1 8.1*** 73.0 8.4***
DSC-R Total Score > 0.7 
(n = 69)
60.0 69.6 50.9 68.3 52.3 47.6
Preference for 
Weight Change
Lose weight 
(n = 113)
68.5 -1.9 77.9 -1.4 60.2 -1.2 77.1 -1.3 61.2 -3.1** 57.9 -2.1*
Stay same 
(n = 16)
79.5 86.3 67.5 84.2 77.9 70.0
Experienced 
Hypoglycemia
During the Day
Yes (n = 53) 65.7 -2.2* 75.8 -1.5 57.1 -2.1* 74.2 -2.1* 58.7 -2.5* 56.0 -2.0*
No (n = 74) 73.9 82.1 65.1 82.0 67.7 63.4
Experienced 
Hypoglycemia
During the Night
Yes (n = 23) 60.5 -2.6** 70.4 -2.0 50.0 -3.1** 66.1 -3.7*** 55.7 -2.2* 53.5 -1.9
No (n = 101) 73.0 82.1 64.8 81.8 65.8 62.3
Experienced 
Hyperglycemia
Yes (n = 64) 67.3 -1.5 76.3 -1.6 57.5 -2.0* 75.2 -1.9 62.4 -0.7 54.8 -2.9**
No (n = 63) 73.1 82.3 65.2 81.7 65.0 65.2
Type of Treatment Injectable 
(n = 31)
65.5 -1.1 73.5 -1.2 54.7 -1.6 74.8 -0.7 58.7 -1.4 52.4 -1.6
Oral only 
(n = 85)
70.9 80.1 62.5 78.0 64.7 61.0
ADS = Appraisal of Diabetes Scale; DSC-R = Diabetes Symptom Checklist – Revised; PGWB = Psychological General Well-Being Index; VAS = Visual Analog Scale; *p < 0.05; **p < 0.01; ***p 
< 0.001Health and Quality of Life Outcomes 2007, 5:47 http://www.hqlo.com/content/5/1/47
Page 10 of 11
(page number not for citation purposes)
the specific aims of each study. The generic measures
examined in the current study can complement previously
validated condition-specific measures by providing an
estimate of overall HRQL and allowing for comparisons
across trials and populations.
Results of the current study are limited by the fact that
data are only available at one point in time. Conse-
quently, neither test-retest reliability nor responsiveness
to change could be evaluated. Evaluation of responsive-
ness using longitudinal data is needed to ensure that the
EQ-5D and PGWB would be sensitive to change in
patients' condition when true change has occurred in
either a clinical trial or naturalistic setting. It is hoped that
longitudinal studies will build on the current findings by
examining these measurement properties of the EQ-5D,
PGWB, and other generic instruments in patients with
type 2 diabetes.
Conclusion
Psychometric instrument evaluation is an ongoing proc-
ess, and confidence in a PRO's performance is strength-
ened as data accumulate from multiple studies and
samples [55]. The current study provides initial data sug-
gesting that the EQ-5D and PGWB are appropriate for use
in patients with type 2 diabetes, and future research may
provide additional support for this conclusion.
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